Devatis Tofacitinib: Uses, Side Effects and Dosage

Serious warnings and precautions box

Serious Infections

• You should NOT take DEVATIS TOFACITINIB if you have an active infection.
• DEVATIS TOFACITINIB is a medicine that affects your immune system. It can lower the ability of your body to fight infections such as tuberculosis, shingles (herpes zoster) and infections caused by other bacteria, fungi, or viruses that can spread throughout the body.
• In some cases, these infections may lead to hospitalization or death.
• Most patients who developed infections were taking other medicines, such as methotrexate or corticosteroids at the same time. These medicines make it harder to fight infections.
• Your healthcare professional will closely monitor you for the signs and symptoms of infections during and after the treatment with DEVATIS TOFACITINIB.

• Contact your healthcare professional if you have any signs or symptoms of an infection, such as:

  • fever, sweating, or chills,
  • muscle aches,
  • cough, shortness of breath,
  • blood in spit,
  • weight loss,
  • warm, red, or painful skin or sores on your body,
  • diarrhea or stomach pain,
  • burning when you urinate or urinating more often than normal,
  • feeling very tired.
• If a serious infection develops, stop taking DEVATIS TOFACITINIB and contact your healthcare professional right away.

Cancers and immune conditions

• Lymphoma, lung cancer, and other cancers have been reported in patients treated with tofacitinib.
• Your healthcare professional will closely monitor you for signs and symptoms of cancer and other serious conditions during treatment with DEVATIS TOFACITINIB.

Blood clots

• Blood clots in the veins of your legs or arms (deep vein thrombosis, DVT), arteries (arterial thrombosis) or lungs (pulmonary embolism, PE) can happen in some people taking DEVATIS TOFACITINIB. This may be life-threatening and cause death.

• Stop taking DEVATIS TOFACITINIB and seek medical help right away if you develop any signs or symptoms of:

  • Blood clots in your leg (such as swelling, pain or tenderness); or
  • Blood clots in your lung (such as sudden unexplained chest pain or shortness of breath).

Major heart problems

• Major heart problems have been reported in Rheumatoid Arthritis patients treated with tofacitinib.
• Talk to your healthcare professional about possible heart disease risk factors before you start taking DEVATIS TOFACITINIB.

• If you develop signs and symptoms of a heart problem, stop taking DEVATIS TOFACITINIB and contact your healthcare professional right away. Symptoms may include:

  • new or worsening chest pain,
  • shortness of breath,
  • irregular heartbeats,
  • swelling of the legs.

What is DEVATIS TOFACITINIB used for?

• Rheumatoid Arthritis

  DEVATIS TOFACITINIB is used to treat adults with rheumatoid arthritis (RA) when other treatments do not work. DEVATIS TOFACITINIB may be taken alone or in combination with methotrexate.

• Psoriatic Arthritis

  DEVATIS TOFACITINIB is used to treat adults with active psoriatic arthritis (PsA) when other medicines do not work. DEVATIS TOFACITINIB may be taken alone or in combination with methotrexate or other medicines called conventional synthetic disease modifying antirheumatic drugs (csDMARDs).

• Ankylosing Spondylitis

  DEVATIS TOFACITINIB is used to treat adults with active ankylosing spondylitis (AS) when other medicines do not work or are not appropriate. Ankylosing spondylitis is a disease that primarily causes inflammation in the spine.

• Active Juvenile Idiopathic Arthritis (JIA)

  DEVATIS TOFACITINIB is used in children (body weight of 40 kg or higher), when other medicines do not work or are not appropriate, to treat:

  • active polyarticular juvenile idiopathic arthritis (pJIA). This is a long‑term disease that mainly

    causes joint pain and swelling.

  • juvenile psoriatic arthritis (jPSA). This is a disease that causes joint pain and inflammation along with a skin problem called psoriasis.

DEVATIS TOFACITINIB may be taken alone or together with methotrexate depending on the patient.

• Ulcerative Colitis

  DEVATIS TOFACITINIB is used to treat adults with moderately to severely active ulcerative colitis (UC) when other medicines do not work.

How does DEVATIS TOFACITINIB work?

DEVATIS TOFACITINIB is a Janus Kinase (JAK) inhibitor. JAK is a type of enzyme which helps start the immune response in your body. DEVATIS TOFACITINIB is believed to interfere with the activity of the JAK enzyme to reduce the immune response. This helps reduce signs and symptoms of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.

What are the ingredients in DEVATIS TOFACITINIB?

Medicinal ingredients: Tofacitinib citrate Non-medicinal ingredients:

5 mg tablet core contains: Microcrystalline Cellulose, Lactose Monohydrate, Croscarmellose Sodium, Magnesium Stearate. The film coat contains: Hypromellose, titanium dioxide, lactose monohydrate, polyethylene glycol/macrogol, triacetin

10 mg tablet core contains: Microcrystalline Cellulose, Lactose Monohydrate, Croscarmellose Sodium, Magnesium Stearate. The film coat contains: Hypromellose, titanium dioxide, lactose monohydrate, polyethylene glycol/macrogol, triacetin, FD&C blue #2/indigo carmine aluminum lake, FD&C blue #1/brilliant blue FCF aluminum lake.

DEVATIS TOFACITINIB comes in the following dosage forms:

5 mg and 10 mg tablets in bottles or foil blisters.

Do not use DEVATIS TOFACITINIB if:

• you are allergic to tofacitinib or any other non-medicinal ingredients in DEVATIS TOFACITINIB.

• you are pregnant or are planning to become pregnant.

• you are breast-feeding or intend to breast-feed. Talk to your healthcare professional about the best way to feed your baby while taking DEVATIS TOFACITINIB.
• you have severe liver problems.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take DEVATIS TOFACITINIB. Talk about any health conditions or problems you may have, including if you:

• are being treated for an infection, get a lot of infections or have infections that keep coming back;
• have diabetes, HIV/AIDS, or a weak immune system. People with these conditions have a higher chance for infections;
• have tuberculosis, or a history of tuberculosis or have been in close contact with someone with tuberculosis;
• have or have had hepatitis B or C;

• have gastrointestinal problems, including gastrointestinal perforations (tear in the stomach or intestines), diverticulitis (inflammation in parts of the large intestine), ulcers in your stomach or

  • intestines;
• have low blood counts. Treatment with DEVATIS TOFACITINIB can be associated with low red blood cell counts (anemia), or with low white blood cell counts (neutrophils or lymphocytes);
• have high cholesterol;
• have or have had any type of cancer;
• have liver problems;
• have kidney problems;
• have a history of interstitial lung disease (diseases that inflame or scar lung tissue);
• have muscle pain or muscle weakness;
• develop new skin lesions during or after therapy or if existing lesions change appearance;
• have received any vaccines (shots) within 1 month prior to starting DEVATIS TOFACITINIB or are planning to get vaccinated. Certain types of vaccines (shots) should not be given when taking DEVATIS TOFACITINIB. Before you start DEVATIS TOFACITINIB, you should be up to date with all recommended vaccinations, including a shingles vaccine;
• have had blood clots in your legs (deep vein thrombosis) or lungs (pulmonary embolism) or have been told you are at risk of blood clots;
• have problems with your blood clotting (thrombophilia);

• have chest pain, heart failure or any heart problems, or heart disease risk factors, such as if you:

  • are a current or past smoker,
  • have high blood pressure (hypertension),
  • have diabetes,
  • have a family history of premature coronary heart disease,
  • have had coronary artery disease. This is when blood vessels that supply your heart are clogged;
• have other diseases associated with rheumatoid arthritis, such as: lumps (nodules), anemia, lung problems, a type of immune problem called Sjögren’s syndrome.
• are of Asian descent. You may be at increased risk of serious side effects.
• have risk factors for broken bones, such as if you: are older than 65 years of age, are a woman, or take a type of medicine called corticosteroids.

Other warnings you should know about: Blood tests and monitoring

You may need blood tests before you start DEVATIS TOFACITINIB. These tests may be repeated while you are taking DEVATIS TOFACITINIB. Your healthcare professional will also monitor your liver tests and blood cholesterol levels 4 to 8 weeks after you start receiving DEVATIS TOFACITINIB and routinely thereafter. These will help your healthcare professional find out how DEVATIS TOFACITINIB is affecting your blood and how well your liver is working.

Female patients

Pregnancy, breastfeeding and birth control

• Avoid becoming pregnant while taking DEVATIS TOFACITINIB. It may harm your unborn baby.
• If you are of child-bearing age, use an effective method of birth control while taking DEVATIS TOFACITINIB. Continue using birth control for 4 to 6 weeks after you stop taking DEVATIS TOFACITINIB.
• Do not use DEVATIS TOFACITINIB while breastfeeding as this medicine can pass into your milk.

Adults aged 65 years and older

Side effects, including serious side effects, have occurred more often in patients aged 65 years and older.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with DEVATIS TOFACITINIB:

• other medicines used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or ulcerative colitis, including:

  • Biologics such as: abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, secukinumab, ustekimumab, vedolizumab,
  • Other JAK inhibitors such as: baricitinib and upadacitinib.
• medicines that affect your immune system (such as azathioprine, 6-mercaptopurine, tacrolimus, sirolimus, cyclosporine)
• antiarrhythmics (medicines used to treat heart rhythm problems)
• beta-blockers (medicines used to slow the heart or lower blood pressure), and calcium channel blockers (medicines used to lower blood pressure)
• cholinesterase inhibitors (medicines used to treat Alzheimer’s)
• HIV protease inhibitors
• a medicine used to treat bacterial infections like tuberculosis called rifampin, and medicines for fungal infections (such as ketoconazole, fluconazole)
• grapefruit juice
• St. John’s Wort (an herbal medicine also known as hypericum perforatum). It may reduce the response to DEVATIS TOFACITINIB.

How to take DEVATIS TOFACITINIB:

• Always take DEVATIS TOFACITINIB exactly as your healthcare professional tells you.

• DEVATIS TOFACITINIB can be taken with or without food.

• Your doctor may reduce the dose if you have liver or kidney problems. You should not increase the dose.
• DEVATIS TOFACITINIB should not be used if you have or develop a serious infection until the infection is controlled.

Your healthcare professional may prescribe DEVATIS TOFACITINIB alone or in combination with other medication(s). If you receive treatment with another drug, your healthcare professional will tell you how to take it. Be sure to read the package leaflets for the other drugs as well as this one.

Usual dose:

Adults (18 years and older):

Rheumatoid Arthritis:

• The recommended dose is 5 mg taken by mouth twice daily.

Psoriatic Arthritis:

• The recommended dose is 5 mg, taken by mouth twice daily.

Ankylosing spondylitis:

• The recommended dose is 5 mg, taken by mouth twice daily.

Ulcerative Colitis:

• The recommended dose is 10 mg, twice daily for the first 8 weeks. After 8 weeks, your doctor will decide to give you 5 mg or 10 mg twice daily for maintenance.
• Your doctor may decide to stop your treatment with DEVATIS TOFACITINIB if it does not work for you within 16 weeks.

Children (body weight of at least 40 kg, less than 18 years old):

Active Juvenile Idiopathic Arthritis (JIA):

• Body weight is at least 40 kg: the recommended dose is one 5 mg tablet, taken twice daily.

Overdose:

Missed Dose:

If you have missed your dose of DEVATIS TOFACITINIB, take the next dose as planned at the next scheduled time. Do NOT take a double dose to make up for a forgotten dose.

Possible side effects from using DEVATIS TOFACITINIB?

These are not all the possible side effects you may have when taking DEVATIS TOFACITINIB. If you experience any side effects not listed here, tell your healthcare professional.

The side effects of tofacitinib include:

• Upper respiratory tract infection (such as a cold)
• Nasopharyngitis (nose or throat infection, runny or stuffy nose), cough
• Headache, dizziness
• Diarrhea, vomiting, nausea (feeling queasy, feeling like you may throw up)
• Indigestion (heartburn or upset stomach)
• Back pain, joint pain
• Rash, acne
• Muscle weakness/pain

If any of the above affects you severely, tell your healthcare professional.

DEVATIS TOFACITINIB may cause abnormal blood test results, including changes in cholesterol levels, white or red blood cell counts or creatinine levels (a protein that may increase in people with kidney problems). Your healthcare professional will decide when to perform blood tests and will interpret the results.

If you think you, or a person you are caring for, have taken too much DEVATIS TOFACITINIB, contact a healthcare professional, hospital emergency department, or regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Serious side effects and what to do about them

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Storage:

Store between 15°C and 30°C.

Keep out of reach and sight of children.

If you want more information about DEVATIS TOFACITINIB:

• Talk to your healthcare professional

• Find the full product monograph that is prepared for healthcare professionals and includes the

  Patient Medication Information by visiting the Health Canada Drug Product Database website

  (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drugproduct-

  database.html); the manufacturer’s website https://devatis.ca/; or by calling the distributor’s phone number 1 (855) 219-0811.

Date of Authorization: 2026-07-21

Reporting side effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

• Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
• Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.